This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barouch, D. H. Articles by Letvin, N. L. Search for Related Content PubMed PubMed Citation Articles by Barouch, D. H. Articles by Letvin, N. L.

Plasmid Chemokines and Colony-Stimulating Factors Enhance the Immunogenicity of DNA Priming-Viral Vector Boosting Human Immunodeficiency Virus Type 1 Vaccines

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215,¹ Vaccine Research Center, National Institutes of Health, Bethesda, Maryland 20892²

Received 19 March 2003/ Accepted 28 May 2003

Heterologous "prime-boost" regimens that involve priming with plasmid DNA vaccines and boosting with recombinant viral vectors have been shown to elicit potent virus-specific cytotoxic T-lymphocyte responses. Increasing evidence, however, suggests that the utility of recombinant viral vectors in human populations will be significantly limited by preexisting antivector immunity. Here we demonstrate that the coadministration of plasmid chemokines and colony-stimulating factors with plasmid DNA vaccines markedly increases the immunogenicity of DNA prime-recombinant adenovirus serotype 5 (rAd5) boost and DNA prime-recombinant vaccinia virus (rVac) boost vaccine regimens in BALB/c mice. In mice with preexisting anti-Ad5 immunity, priming with the DNA vaccine alone followed by rAd5 boosting elicited only marginal immune responses. In contrast, cytokine-augmented DNA vaccine priming followed by rAd5 vector boosting was able to generate potent immune responses in mice with preexisting anti-Ad5 immunity. These data demonstrate that plasmid cytokines can markedly improve the immunogenicity of DNA prime-viral vector boost vaccine strategies and can partially compensate for antivector immunity.

This article has been cited by other articles:

• Rodriguez, A., Goudsmit, J., Companjen, A., Mintardjo, R., Gillissen, G., Tax, D., Sijtsma, J., Weverling, G. J., Holterman, L., Lanar, D. E., Havenga, M. J. E., Radosevic, K. (2008). Impact of Recombinant Adenovirus Serotype 35 Priming versus Boosting of a Plasmodium falciparum Protein: Characterization of T- and B-Cell Responses to Liver-Stage Antigen 1. Infect. Immun. 76: 1709-1718 [Abstract] [Full Text]  
• Schaubert, K. L., Price, D. A., Frahm, N., Li, J., Ng, H. L., Joseph, A., Paul, E., Majumder, B., Ayyavoo, V., Gostick, E., Adams, S., Marincola, F. M., Sewell, A. K., Altfeld, M., Brenchley, J. M., Douek, D. C., Yang, O. O., Brander, C., Goldstein, H., Kan-Mitchell, J. (2007). Availability of a Diversely Avid CD8+ T Cell Repertoire Specific for the Subdominant HLA-A2-Restricted HIV-1 Gag p2419-27 Epitope. J. Immunol. 178: 7756-7766 [Abstract] [Full Text]  
• Breton, M., Zhao, C., Ouellette, M., Tremblay, M. J., Papadopoulou, B. (2007). A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection. J. Gen. Virol. 88: 217-225 [Abstract] [Full Text]  
• Thorner, A. R., Lemckert, A. A. C., Goudsmit, J., Lynch, D. M., Ewald, B. A., Denholtz, M., Havenga, M. J. E., Barouch, D. H. (2006). Immunogenicity of Heterologous Recombinant Adenovirus Prime-Boost Vaccine Regimens Is Enhanced by Circumventing Vector Cross-Reactivity. J. Virol. 80: 12009-12016 [Abstract] [Full Text]  
• Kornbluth, R. S., Stone, G. W. (2006). Immunostimulatory combinations: designing the next generation of vaccine adjuvants. J. Leukoc. Biol. 80: 1084-1102 [Abstract] [Full Text]  
• Lemckert, A. A. C., Grimbergen, J., Smits, S., Hartkoorn, E., Holterman, L., Berkhout, B., Barouch, D. H., Vogels, R., Quax, P., Goudsmit, J., Havenga, M. J. E. (2006). Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity.. J. Gen. Virol. 87: 2891-2899 [Abstract] [Full Text]  
• Ferrone, C. R., Perales, M.-A., Goldberg, S. M., Somberg, C. J., Hirschhorn-Cymerman, D., Gregor, P. D., Turk, M. J., Ramirez-Montagut, T., Gold, J. S., Houghton, A. N., Wolchok, J. D. (2006). Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin fc domains.. Clin. Cancer Res. 12: 5511-5519 [Abstract] [Full Text]  
• Havenga, M., Vogels, R., Zuijdgeest, D., Radosevic, K., Mueller, S., Sieuwerts, M., Weichold, F., Damen, I., Kaspers, J., Lemckert, A., van Meerendonk, M., van der Vlugt, R., Holterman, L., Hone, D., Skeiky, Y., Mintardjo, R., Gillissen, G., Barouch, D., Sadoff, J., Goudsmit, J. (2006). Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells.. J. Gen. Virol. 87: 2135-2143 [Abstract] [Full Text]  
• Cayabyab, M. J., Hovav, A.-H., Hsu, T., Krivulka, G. R., Lifton, M. A., Gorgone, D. A., Fennelly, G. J., Haynes, B. F., Jacobs, W. R. Jr., Letvin, N. L. (2006). Generation of CD8+ T-Cell Responses by a Recombinant Nonpathogenic Mycobacterium smegmatis Vaccine Vector Expressing Human Immunodeficiency Virus Type 1 Env. J. Virol. 80: 1645-1652 [Abstract] [Full Text]  
• Nanda, A., Lynch, D. M., Goudsmit, J., Lemckert, A. A. C., Ewald, B. A., Sumida, S. M., Truitt, D. M., Abbink, P., Kishko, M. G., Gorgone, D. A., Lifton, M. A., Shen, L., Carville, A., Mansfield, K. G., Havenga, M. J. E., Barouch, D. H. (2005). Immunogenicity of Recombinant Fiber-Chimeric Adenovirus Serotype 35 Vector-Based Vaccines in Mice and Rhesus Monkeys. J. Virol. 79: 14161-14168 [Abstract] [Full Text]  
• Hashimoto, M., Boyer, J. L., Hackett, N. R., Wilson, J. M., Crystal, R. G. (2005). Induction of Protective Immunity to Anthrax Lethal Toxin with a Nonhuman Primate Adenovirus-Based Vaccine in the Presence of Preexisting Anti-Human Adenovirus Immunity. Infect. Immun. 73: 6885-6891 [Abstract] [Full Text]  
• Lemckert, A. A. C., Sumida, S. M., Holterman, L., Vogels, R., Truitt, D. M., Lynch, D. M., Nanda, A., Ewald, B. A., Gorgone, D. A., Lifton, M. A., Goudsmit, J., Havenga, M. J. E., Barouch, D. H. (2005). Immunogenicity of Heterologous Prime-Boost Regimens Involving Recombinant Adenovirus Serotype 11 (Ad11) and Ad35 Vaccine Vectors in the Presence of Anti-Ad5 Immunity. J. Virol. 79: 9694-9701 [Abstract] [Full Text]  
• Barouch, D. H., Yang, Z.-y., Kong, W.-p., Korioth-Schmitz, B., Sumida, S. M., Truitt, D. M., Kishko, M. G., Arthur, J. C., Miura, A., Mascola, J. R., Letvin, N. L., Nabel, G. J. (2005). A Human T-Cell Leukemia Virus Type 1 Regulatory Element Enhances the Immunogenicity of Human Immunodeficiency Virus Type 1 DNA Vaccines in Mice and Nonhuman Primates. J. Virol. 79: 8828-8834 [Abstract] [Full Text]  
• Hutchings, C. L., Gilbert, S. C., Hill, A. V. S., Moore, A. C. (2005). Novel Protein and Poxvirus-Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell-Mediated Immunity. J. Immunol. 175: 599-606 [Abstract] [Full Text]  
• Sumida, S. M., Truitt, D. M., Lemckert, A. A. C., Vogels, R., Custers, J. H. H. V., Addo, M. M., Lockman, S., Peter, T., Peyerl, F. W., Kishko, M. G., Jackson, S. S., Gorgone, D. A., Lifton, M. A., Essex, M., Walker, B. D., Goudsmit, J., Havenga, M. J. E., Barouch, D. H. (2005). Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein. J. Immunol. 174: 7179-7185 [Abstract] [Full Text]  
• Santra, S., Seaman, M. S., Xu, L., Barouch, D. H., Lord, C. I., Lifton, M. A., Gorgone, D. A., Beaudry, K. R., Svehla, K., Welcher, B., Chakrabarti, B. K., Huang, Y., Yang, Z.-Y., Mascola, J. R., Nabel, G. J., Letvin, N. L. (2005). Replication-Defective Adenovirus Serotype 5 Vectors Elicit Durable Cellular and Humoral Immune Responses in Nonhuman Primates. J. Virol. 79: 6516-6522 [Abstract] [Full Text]  
• Nordstrom, E. K. L., Forsell, M. N. E., Barnfield, C., Bonin, E., Hanke, T., Sundstrom, M., Karlsson, G. B., Liljestrom, P. (2005). Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1. J. Gen. Virol. 86: 349-354 [Abstract] [Full Text]  
• Holterman, L., Vogels, R., van der Vlugt, R., Sieuwerts, M., Grimbergen, J., Kaspers, J., Geelen, E., van der Helm, E., Lemckert, A., Gillissen, G., Verhaagh, S., Custers, J., Zuijdgeest, D., Berkhout, B., Bakker, M., Quax, P., Goudsmit, J., Havenga, M. (2004). Novel Replication-Incompetent Vector Derived from Adenovirus Type 11 (Ad11) for Vaccination and Gene Therapy: Low Seroprevalence and Non-Cross-Reactivity with Ad5. J. Virol. 78: 13207-13215 [Abstract] [Full Text]  
• Nakaya, Y., Nakaya, T., Park, M.-S., Cros, J., Imanishi, J., Palese, P., Garcia-Sastre, A. (2004). Induction of Cellular Immune Responses to Simian Immunodeficiency Virus Gag by Two Recombinant Negative-Strand RNA Virus Vectors. J. Virol. 78: 9366-9375 [Abstract] [Full Text]  
• Barouch, D. H., Pau, M. G., Custers, J. H. H. V., Koudstaal, W., Kostense, S., Havenga, M. J. E., Truitt, D. M., Sumida, S. M., Kishko, M. G., Arthur, J. C., Korioth-Schmitz, B., Newberg, M. H., Gorgone, D. A., Lifton, M. A., Panicali, D. L., Nabel, G. J., Letvin, N. L., Goudsmit, J. (2004). Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity. J. Immunol. 172: 6290-6297 [Abstract] [Full Text]  
• Giri, M., Ugen, K. E., Weiner, D. B. (2004). DNA Vaccines against Human Immunodeficiency Virus Type 1 in the Past Decade. Clin. Microbiol. Rev. 17: 370-389 [Abstract] [Full Text]  
• Sumida, S. M., Truitt, D. M., Kishko, M. G., Arthur, J. C., Jackson, S. S., Gorgone, D. A., Lifton, M. A., Koudstaal, W., Pau, M. G., Kostense, S., Havenga, M. J. E., Goudsmit, J., Letvin, N. L., Barouch, D. H. (2004). Neutralizing Antibodies and CD8+ T Lymphocytes both Contribute to Immunity to Adenovirus Serotype 5 Vaccine Vectors. J. Virol. 78: 2666-2673 [Abstract] [Full Text]